Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-0.35 |
-0.3 |
0.05 |
14.29% |
2024-03-08 |
2023-12 |
-0.37 |
N/A |
N/A |
N/A |
2024-03-08 |
2023-12 |
-0.37 |
-0.25 |
0.12 |
32.43% |
2023-11-07 |
2023-09 |
-0.46 |
-0.25 |
0.21 |
45.65% |
2023-11-07 |
2023-09 |
-0.46 |
N/A |
N/A |
N/A |
2023-08-08 |
2023-06 |
-0.52 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-09 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-17 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-17 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-05-09 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-05-09 |
Wedbush |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-11-12 |
AVALON VENTURES XI, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2021-06-14 |
BREGUA CORP |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-11-12 |
LICHTER JAY |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2021-12-28 |
ORBIMED ADVISORS, L.L.C. |
Director |
0.00 |
Sale |
2023-07-18 |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-11-12 |
REARDON TIGHE |
Chief Financial Officer |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
RA Capital Management, L.P. |
8.67M |
102.92M |
18.81% |
2023-06-29 |
FMR, LLC |
5.06M |
60.10M |
10.98% |
2023-06-29 |
BVF Inc. |
4.11M |
48.75M |
8.91% |
2023-06-29 |
Orbimed Advisors LLC. |
2.84M |
33.67M |
6.15% |
2023-06-29 |
Citadel Advisors Llc |
2.12M |
25.11M |
4.59% |
2023-06-29 |
Janus Henderson Group PLC |
2.11M |
25.04M |
4.58% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
Fidelity Growth Company Fund |
729.43K |
8.02M |
1.58% |
2023-07-30 |
Fidelity Series Small Cap Opportunities Fund |
704.43K |
9.86M |
1.53% |
2023-07-30 |
Fidelity Small Cap Growth Fund |
654.42K |
9.16M |
1.42% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
585.68K |
8.20M |
1.27% |
2023-06-29 |
Janus Henderson Global Life Sciences Fund |
575.43K |
6.83M |
1.25% |
2023-08-30 |
Fidelity Select Portfolios - Health Care |
500.00K |
5.50M |
1.08% |